127,588 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Eversept Partners LP

Eversept Partners LP bought a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 127,588 shares of the company's stock, valued at approximately $10,444,000. Vaxcyte accounts for about 0.9% of Eversept Partners LP's investment portfolio, making the stock its 23rd largest holding. Eversept Partners LP owned approximately 0.10% of Vaxcyte at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Vaxcyte by 4.6% during the 4th quarter. Vanguard Group Inc. now owns 11,961,687 shares of the company's stock valued at $979,184,000 after buying an additional 521,204 shares during the period. Capital Research Global Investors boosted its holdings in Vaxcyte by 26.8% during the fourth quarter. Capital Research Global Investors now owns 6,210,523 shares of the company's stock valued at $508,393,000 after acquiring an additional 1,312,302 shares during the period. Franklin Resources Inc. grew its holdings in Vaxcyte by 3.0% in the 4th quarter. Franklin Resources Inc. now owns 2,869,332 shares of the company's stock valued at $234,884,000 after buying an additional 82,997 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Vaxcyte by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company's stock valued at $229,495,000 after purchasing an additional 102,106 shares during the period. Finally, Alliancebernstein L.P. increased its stake in Vaxcyte by 8.1% during the fourth quarter. Alliancebernstein L.P. now owns 1,779,362 shares of the company's stock valued at $145,659,000 after acquiring an additional 133,448 shares during the period. 96.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a research note on Tuesday, April 8th. The Goldman Sachs Group cut their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Cantor Fitzgerald began coverage on Vaxcyte in a report on Tuesday. They issued an "overweight" rating on the stock. Finally, Bank of America decreased their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Vaxcyte currently has an average rating of "Buy" and an average target price of $136.50.

Insiders Place Their Bets

In related news, CFO Andrew Guggenhime sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total value of $670,800.00. Following the sale, the chief financial officer now owns 109,491 shares of the company's stock, valued at approximately $9,180,820.35. This trade represents a 6.81 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 24,000 shares of company stock worth $1,946,720 over the last ninety days. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Price Performance

Shares of NASDAQ PCVX traded down $1.59 during mid-day trading on Friday, hitting $32.92. The company's stock had a trading volume of 1,638,022 shares, compared to its average volume of 1,232,219. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06. The company's fifty day simple moving average is $56.56 and its 200-day simple moving average is $80.88. The stock has a market cap of $4.24 billion, a price-to-earnings ratio of -7.16 and a beta of 1.26.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. On average, sell-side analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.